ChemicalBook > CAS DataBase List > Cefmenoxime

Cefmenoxime

Cefmenoxime Structure
Cefmenoxime
  • CAS No.65085-01-0
  • Chemical Name:Cefmenoxime
  • CBNumber:CB7771510
  • Molecular Formula:C16H17N9O5S3
  • Formula Weight:511.56
  • MOL File:65085-01-0.mol
Cefmenoxime Property
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal word
  • Hazard statements
  • Precautionary statements

Cefmenoxime Chemical Properties,Usage,Production

  • Originator Tacef,Takeda,W. Germany,1983
  • Uses Antibacterial.
  • Definition ChEBI: A third-generation cephalosporin antibiotic, bearing a 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino group at the 7beta-position and a [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl group at the 3-position.
  • Manufacturing Process 7β-[α-Methoxyimino-α-(2-aminothiazol-4-yl)acetamido]cephalosporanicacid trifluoroacetic acid salt is dissolved in a solution of 272 mg of 1-methyl-5- mercapto-1H-tetrazole, 555 mg of sodium bicarbonate and 68 mg of triethylbenzylammonium bromide in 10 ml of water. The solution is heated at 60°C in nitrogen atmosphere for 6 hours. After cooling, the reaction solution is passed through a column of Amberlite XAD-2 and eluted with water and then with 2.5% ethanol. The procedure yields sodium 7β-[α-methoxyimino-α- (2-aminothiazol-4-yl)acetamido]-3-(1-methyl-1H-tetrazol-5-ylthiomethyl)-3- cephem-4-carboxylate, MP 174°C to 175°C (decomposition).
  • brand name Cefmax (TAP).
  • Therapeutic Function Antibacterial
  • Antimicrobial activity A semisynthetic cephalosporin supplied as the hydrochloride. Its activity is very similar to that of cefotaxime. A 500 mg intramuscular injection achieves a plasma concentration of 15 mg/L after 40 min. A concentration of 200 mg/L is attained after intravenous administration of 1 g. The plasma half-life is c. 1 h. Around 77% is protein bound. Probenecid increases peak plasma levels and extends the plasma half-life to 1.8 h. Therapeutic concentrations are achieved in CSF. There is a degradation product with a long half-life (around 40 h), but 80–92% of the drug is recovered unchanged from the urine. In patients with renal insufficiency, no significant relation was found between creatinine clearance and peak serum concentrations but there was a linear relationship with plasma half-life and total body clearance. About 10% of the dose appears in the feces, mostly extensively degraded, possibly by the fecal flora.
    Toxicity, side effects and clinical use are those common to group 4 cephalosporins.
Cefmenoxime Preparation Products And Raw materials
Raw materials
Preparation Products
Global(77)Suppliers
  • Supplier:
    Guangzhou PI PI Biotech Inc
  • Tel:+8618371201331
  • Fax:020-81716319
  • Email:sales@pipitech.com;87478684@qq.com
  • Country:China
  • ProdList:3245
  • Advantage:55
  • Supplier:
    Shanghai Yingrui Biopharma Co., Ltd.
  • Tel:+86-21-33585366 E-mail:sales03@shyrchem.com
  • Fax:+86-21-34979012
  • Email:sales03@shyrchem.com
  • Country:CHINA
  • ProdList:739
  • Advantage:60
  • Supplier:
    career henan chemical co
  • Tel:13203830695 0086-371-86658258
  • Fax:0086-371-86658258
  • Email:factory@coreychem.com
  • Country:CHINA
  • ProdList:29864
  • Advantage:58
  • Supplier:
    Shaanxi Dideu Medichem Co. Ltd
  • Tel:18192503167 +86-29-89586680
  • Fax:+86-29-88380327
  • Email:1005@dideu.com
  • Country:CHINA
  • ProdList:9938
  • Advantage:58
65085-01-0, CefmenoximeRelated Search:
  • CEFMENOXIME
  • (6r-(6alpha,7beta(z)))-7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
  • (6R,7R)-7-[[(Z)-(2-Aminothiazol-4-yl)(methoxyimino)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  • (6R,7R)-7α-[2-(2-Amino-4-thiazolyl)-2-[(Z)-methoxyimino]acetylamino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  • 7β-[[(Z)-(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[(1-methyl-1H-tetrazole-5-yl)thio]methyl]cepham-3-ene-4-carboxylic acid
  • CMX
  • (6R,7R)-7-[(2E)-2-(2-aMino-1,3-thiazol-4-yl)-2-(MethoxyiMino)acetaMido]-3-{[(1-Methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]Methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  • 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6α,7β(Z)]]-
  • 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, (6R,7R)-
  • AB 50912
  • SCE 1365
  • [6R-[6α,7β(Z)]]-7-[[(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-y1)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oet-2-ene-2-carboxylic acid
  • Cefotaxime Isomer
  • (6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-methoxyimino-1-oxoethyl]amino]-3-[[(1-methyl-5-tetrazolyl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  • 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, (6R,7R)-
  • Cefmenoxime USP/EP/BP
  • 65085-01-0
  • C16H17N9O5S3
  • Pharmaceutical intermediate